SCHEMBL1129809

SCHEMBL1129809

CCCCCCCCCCCCCCCCCCNC(=O)NCCc1c[nH]c2ccc(O)cc12

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 11/20 0.78
SPR P35270 3/20 0.68
KDM4E B2RXH2 2/20 0.68
ALDH1A1 P00352 2/20 0.68
NPSR1 Q6W5P4 2/20 0.68
CYP1A2 P05177 1/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2D6 P10635 1/20 0.68
MAPT P10636 1/20 0.68
IDO1 P14902 1/20 0.68
HPGD P15428 1/20 0.68
BLM P54132 1/20 0.68
NOTUM Q6P988 1/20 0.68
FAAH O00519 1/20 0.65
PTGS2 P35354 1/20 0.65
MTNR1A P48039 1/20 0.60
LMNA P02545 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
TSHR P16473 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1130740 1.00 TRPV1 (0.78) TRPV1SPRKDM4EALDH1A1NPSR1
Acetylserotonin SCHEMBL28474145 0.89 SPR (0.86) TRPV1SPRKDM4EALDH1A1NPSR1
Acetylserotonin SCHEMBL28475510 0.89 SPR (0.86) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL13645780 0.88 TRPV1 (0.71) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL23630268 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL23630280 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL23630270 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL23630267 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL1746356 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL23643317 0.87 TRPV1 (1.00) TRPV1SPRKDM4EALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10583119-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2020-03-10 US disclosed
EP-2282735-B1 PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES SIGNUM BIOSCIENCES INC (US) 2019-01-16 EP disclosed
EP-2282735-B1 PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES SIGNUM BIOSCIENCES INC (US) 2019-01-16 EP disclosed
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2017-09-21 US disclosed
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2017-09-21 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
CN-102014897-B Compound, compositions and its preparation method SIGNUM BIOSCIENCES, INC. (US) 2015-08-05 CN disclosed
EP-2282735-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME Signum Biosciences, Inc. (US) 2011-02-16 EP disclosed
WO-2009132051-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2009-10-29 WO disclosed
WO-2009132051-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2009-10-29 WO disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same PPP2CA, PPP4C, PPP6C TRPV1 4687/4885SPR 1640/4885KDM4E 243/4885
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME PPP2CA, PPP4C, PPP6C TRPV1 4687/4885SPR 1640/4885KDM4E 243/4885
US-10583119-B2 Compounds, compositions and methods for making the same PPP2CA, PPP4C, PPP6C TRPV1 4687/4885SPR 1640/4885KDM4E 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.